

Corrections

Correction in the article by the SEC Working Group and Expert Reviewers for the 2019 ESC/EAS guidelines for the management of dyslipidaemias, and SEC Guidelines Committee “Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias”, Rev Esp Cardiol. 2020;73:348–353



Corrección en el artículo del Grupo de Trabajo y revisores expertos de la SEC para la guía ESC 2019 sobre el tratamiento de las dislipemias, y Comité de Guías de la SEC «Comentarios a la guía ESC/EAS 2019 sobre el tratamiento de las dislipemias», Rev Esp Cardiol. 2020;73:348–353

In the article “Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias”, an error was detected in [table 2](#). In line 4, High, column 5, Relative reduction in LDL-C, the value $\geq 50\%$ was missing.

The correct table is:

Table 2

Cardiovascular risk stratification and therapeutic goals for diabetic patients

Risk category	Characteristics			Therapeutic goal	
	TOL	Additional CVRFs	DM timeline	Relative LDL-C reduction	Absolute value (mg/dL)
Very high	Yes	≥ 3	Duration of DM1 > 20 y	$\geq 50\%$	< 55
High	No	1	Duration > 10 y	$\geq 50\%$	< 70
Moderate	No	No	Young diabetics: DM1, < 35 y DM2, age < 50 y and duration < 10 y		< 100
Low	[0,2-6]	No diabetics are considered to be low risk			

CVRF, cardiovascular risk factors; DM1, type 1 diabetes mellitus; DM2, type 2 diabetes mellitus; LDL-C, low-density lipoprotein cholesterol; TOL, target organ lesion.

This correction has been made to the electronic version of the article on 12th October 2020.

SEE RELATED CONTENT:

<https://doi.org/10.1016/j.rec.2019.11.019>

<https://doi.org/10.1016/j.rec.2020.10.016>

1885-5857/© 2021 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.